PAG
SUPN icon

Private Advisor Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Private Advisor Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,100
Closed -$219K – 1506
2017
Q2 		$219K Buy
+5,100
New +$182K 0.01% 1221

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Private Advisor Group's SUPN Position: Q3 2017 in Review

Private Advisor Group sold out of Supernus Pharmaceuticals (SUPN) in Q3 2017, closing a stake of 5,100 shares — an estimated $219K sold.

Private Advisor Group first reported a position in SUPN in Q2 2017 and held it in 1 quarter. The position peaked at $219K in Q2 2017. 275 funds tracked by Wall St. Rank hold SUPN as of Q3 2017.

  • Private Advisor Group reported no remaining Supernus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Private Advisor Group sold 5,100 Supernus Pharmaceuticals shares in Q3 2017, an estimated $219K.
  • Private Advisor Group first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Private Advisor Group's Supernus Pharmaceuticals position peaked at $219K in Q2 2017.
  • 275 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2017.

Based on Private Advisor Group's 13F filing for Q3 2017, filed 13 Nov 2017.